PHARMACOLOGY UPDATE

Sarilumab Injection (Kevzara)

July 30, 2017

Sarilumab is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have demonstrated an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs.

Issue Date: July 30, 2017

Table of Contents

Financial Disclosure: Internal Medicine Alert’s Physician Editor Stephen Brunton, MD, is a retained consultant for Abbott Diabetes, Actavis, AstraZeneca, Becton Dickinson, Boehringer Ingelheim, Cempra, Janssen, Lilly, Merck, Novo Nordisk, Sanofi, and Teva; he serves on the speakers bureau of AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, and Teva. Contributing Editor Louis Kuritzky, MD, is a retained consultant for and on the speakers bureau of, Allergan, Daiichi Sankyo, Lilly, and Lundbeck. Peer Reviewer Gerald Roberts, MD; Editor Jonathan Springston; Executive Editor Leslie Coplin; and AHC Media Editorial Group Manager Terrey L. Hatcher report no financial relationships relevant to this field of study.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements